<SEC-DOCUMENT>0001193125-17-129652.txt : 20170420
<SEC-HEADER>0001193125-17-129652.hdr.sgml : 20170420
<ACCEPTANCE-DATETIME>20170420065033
ACCESSION NUMBER:		0001193125-17-129652
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170420
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170420
DATE AS OF CHANGE:		20170420

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MEDNAX, INC.
		CENTRAL INDEX KEY:			0000893949
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOSPITALS [8060]
		IRS NUMBER:				263667538
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12111
		FILM NUMBER:		17771353

	BUSINESS ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323
		BUSINESS PHONE:		9543840175

	MAIL ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PEDIATRIX MEDICAL GROUP INC
		DATE OF NAME CHANGE:	19950801
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d286352d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (date of earliest event reported): April&nbsp;20, 2017 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MEDNAX, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
Name of Registrant as Specified in Its Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Florida</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-12111</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">26-3667538</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1301 Concord Terrace </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sunrise, Florida 33323 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) (zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code (954) <FONT STYLE="white-space:nowrap">384-0175</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.02</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Results of Operations and Financial Condition. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;20, 2017, MEDNAX, Inc., a Florida
corporation (the &#147;Company&#148;), issued a press release announcing its preliminary results of operations for the three months ended March&nbsp;31, 2017.&nbsp;A copy of the press release is attached hereto as Exhibit 99.1 and is hereby
incorporated in this Current Report by reference.&nbsp;The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed &#147;filed&#148; with the Securities and Exchange Commission nor incorporated by reference in any
registration statement or other document filed by the Company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.</P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) &nbsp;&nbsp;&nbsp;&nbsp;Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.1&#151;Press Release of
MEDNAX, Inc. dated April&nbsp;20, 2017. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MEDNAX, INC.</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date:&nbsp;&nbsp;April&nbsp;20, 2017</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Vivian Lopez-Blanco</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vivian Lopez-Blanco</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Financial
Officer</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of MEDNAX, Inc. dated April&nbsp;20, 2017.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d286352dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g286352g00g02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FOR MORE INFORMATION: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charles Lynch </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Strategy and Investor Relations
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">954-384-0175,</FONT></FONT> x 5692 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>charles_lynch@mednax.com </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>FOR IMMEDIATE RELEASE
</U></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEDNAX Previews 2017 First Quarter Results </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FORT LAUDERDALE, Fla</B>., April&nbsp;20, 2017 &#150; MEDNAX, Inc. (NYSE: MD), today announced preliminary financial and operating results for the three
months ended March&nbsp;31, 2017. These results are subject to revision upon finalization of the Company&#146;s quarterly accounting and financial reporting procedures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the 2017 first quarter, the Company&#146;s expected results compared to its previously reported anticipated outlook were impacted by the following
factors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Lower same-unit revenue driven by a shift to government payors and lower neonatology volumes which had a combined unfavorable impact of $0.11 per share; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Higher practice compensation expense, primarily for <FONT STYLE="white-space:nowrap">non-physician</FONT> clinicians which had an unfavorable impact of $0.02 per share. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEDNAX expects to report the following results for the 2017 first quarter as compared to the first quarter of 2016: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Net revenue of $836&nbsp;million, compared to $753&nbsp;million; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Net income of $55&nbsp;million, compared to $68&nbsp;million; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">EBITDA of $132&nbsp;million, compared to $144&nbsp;million; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Earnings per share of $0.59, compared to $0.73; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Adjusted EPS of $0.75, compared to $0.87. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the first quarter, same-unit revenue is expected to decline by
0.9&nbsp;percent when compared to the prior year period. Compared to the Company&#146;s expected range of same-unit growth within its previously reported first-quarter outlook of one percent to three percent, this decline in same-unit revenue is
expected to impact Adjusted EPS by $0.11. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Same-unit revenue from net reimbursement-related factors is expected to decline by 0.6&nbsp;percent for the first
quarter of 2017, compared to the first quarter of 2016, driven by a 90 basis point payor mix shift to government payors that impacted same-unit pricing negatively by 150 basis points. Within MEDNAX&#146;s primary clinical specialties, on a same-unit
basis, payor mix for anesthesiology services is expected to shift by 190 basis points to government payors compared to the prior year period, while payor mix for neonatology services is expected to be relatively unchanged. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Same-unit revenue attributable to patient volume is expected to decline by 0.3&nbsp;percent for the first quarter of 2017, compared to the first quarter of
2016. For the 2017 first quarter, same-unit neonatal intensive care unit (NICU) patient days are expected to decline 2.1&nbsp;percent compared to the prior year period (1.0&nbsp;percent when adjusted for one fewer day in 2017), reflecting a decline
in total births at the hospitals where MEDNAX provides neonatology services of 2.9&nbsp;percent (1.8&nbsp;percent when adjusted for one fewer day in 2017). This decline in NICU patient days is expected to impact MEDNAX&#146;s same-unit volume
negatively by approximately 60 basis points. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, higher than expected practice salaries and benefits expense, primarily for <FONT
STYLE="white-space:nowrap">non-physician</FONT> clinicians, is expected to impact the Company&#146;s Adjusted EPS unfavorably by $0.02 from what was anticipated within MEDNAX&#146;s previously reported first-quarter outlook. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Measures </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A
reconciliation of expected EBITDA and expected Adjusted EPS for the three months ended March&nbsp;31, 2017, and reported EBITDA and Adjusted EPS for the three months ended March&nbsp;31, 2016, to the most directly comparable GAAP measures is
provided in the financial tables of this press release. Additionally, historical reconciliations of EBITDA and Adjusted EPS to the most directly comparable GAAP measures are available on the Company&#146;s website at www.mednax.com/investors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Earnings Conference Call </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEDNAX, Inc. will host an investor
conference call and webcast on Thursday, May&nbsp;4, 2017, at 10:00 a.m. ET, to discuss results from operations for the quarter ended March&nbsp;31, 2017. A detailed press release will be issued the morning of May&nbsp;4, 2017, before the securities
markets open. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The investor conference call will be webcast and can be accessed at MEDNAX&#146;s website, <U>www.mednax.com/investors</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ABOUT MEDNAX </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEDNAX, Inc. is a national health solutions
partner comprised of the nation&#146;s leading providers of physician services. Physicians and advanced practitioners practicing as part of MEDNAX are reshaping the delivery of care within their specialties and subspecialties, using evidence-based
tools, continuous quality initiatives, clinical research and telemedicine to enhance patient outcomes and provide high-quality, cost-effective care. The Company was founded in 1979, and </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
today, through its affiliated professional corporations, MEDNAX provides services through a network of more than 3,725 physicians in all 50 states and Puerto Rico. In addition to its national
physician network, MEDNAX provides services to healthcare facilities and physicians in over 40 states through two complementary businesses, consisting of a management services company and a consulting services company. Additional information is
available at www.mednax.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to our
objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements
are often characterized by terminology such as &#147;believe&#148;, &#147;hope&#148;, &#147;may&#148;, &#147;anticipate&#148;, &#147;should&#148;, &#147;intend&#148;, &#147;plan&#148;, &#147;will&#148;, &#147;expect&#148;, &#147;estimate&#148;,
&#147;project&#148;, &#147;positioned&#148;, &#147;strategy&#148; and similar expressions, and are based on assumptions and assessments made by MEDNAX&#146;s management in light of their experience and their perception of historical trends, current
conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and MEDNAX undertakes no duty to update or revise any such statements,
whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and
business decisions to differ materially from forward-looking statements are described in MEDNAX&#146;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and its Quarterly Reports on Form
<FONT STYLE="white-space:nowrap">10-Q,</FONT> including the sections entitled &#147;Risk Factors&#148;, as well MEDNAX&#146;s current reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed with the Securities and Exchange Commission.
</I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEDNAX, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Reconciliation of Expected Net Income Attributable to MEDNAX, Inc. to Expected EBITDA </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended</B><br><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributable to MEDNAX, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">54,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">67,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, net<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">131,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">143,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Interest expense, net is composed of interest expense, investment and other income and equity in earnings of unconsolidated affiliate. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEDNAX, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Reconciliation of Expected Diluted Net Income per Share Attributable to MEDNAX, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>to Expected Adjusted Diluted Net Income per Share Attributable to MEDNAX, Inc. (&#147;Adjusted EPS&#148;) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except per share data) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended</B><br><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average dilutive shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center">93,143</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center">93,091</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income and diluted net income per share attributable to MEDNAX, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">54,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">67,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization (net of tax of $6,843 and $5,118)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation (net of tax of $2,939 and $3,476)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted net income and diluted EPS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">69,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g286352g00g02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g286352g00g02.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M;2VNU5;FWBF"\@2(&Q^= #X(8H(1%#&L<:]%08 _"@!88HX8A'%&L:#.%48
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MRJ@%CZGUH IVNG6,&HS3PV<$<QZR+& WYXI@:-("-(HTDD=457?&Y@,%OK0
M/%&\L;M&I=,[6(Y7/IZ4 'E1^?YOEKYNW;OQSCTSZ4 ,-K;M%-&8(RDA)=2@
MPQ]3ZT />*.2 Q/&K1D8*L,@CZ4 .*J8RA4%2,8QQB@"-K:!X4B:"-HT(*J5
M!"XZ8':@ N;:"ZC"7$$<R Y"R*&&?QH (+:""#R888XXN?D10%_*@!/LUN$A
1'D1XA/[L;1\GT]* )Z /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
